MD Anderson vs Mayo Clinic vs MSK: A Practical Guide to Cancer Second Opinions
A medically neutral decision-support resource for North American and European patients evaluating cancer second opinions at UT MD Anderson Cancer Center, Mayo Clinic, and Memorial Sloan Kettering Cancer Center — covering clinical profiles, access pathways, specialty strengths, international patient considerations, and cost factors.
1. Why Cancer Patients Seek Second Opinions at Major Cancer Centers
Cancer patients seek second opinions at major cancer research centers such as UT MD Anderson Cancer Center, Mayo Clinic, and Memorial Sloan Kettering Cancer Center (MSK) primarily to confirm diagnosis accuracy, explore additional treatment options, access specialized clinical trials, and obtain molecular profiling or genomic analysis that may not be available at community oncology centers. Research consistently shows that second opinions at high-volume cancer centers result in meaningful changes to diagnosis or treatment recommendations in 15–30% of cases.
A cancer diagnosis carries profound implications for treatment planning, quality of life, and long-term outcomes. The decision to proceed with a specific treatment protocol — surgery, radiation, chemotherapy, immunotherapy, or a combination — is rarely straightforward, and the margin for error is clinically significant. For patients who have received an initial oncology assessment at a community hospital or regional cancer center, seeking a second opinion at a major cancer research institution has become an increasingly recognized component of informed cancer care.
Three institutions in particular are referenced most frequently in the context of cancer second opinions among North American and international patients: UT MD Anderson Cancer Center in Houston, Texas; Mayo Clinic with primary oncology services in Rochester, Minnesota; and Memorial Sloan Kettering Cancer Center (MSK) in New York City. Each of these institutions is a designated National Cancer Institute (NCI) Comprehensive Cancer Center — a federal designation reflecting the integration of cancer research, treatment, and education at the highest level of clinical organization.
Understanding what distinguishes these institutions from one another — in clinical specialty focus, access pathways, cost structure, international patient services, and practical logistics — is the foundation of an informed second opinion decision. This resource is designed to support that evaluation without advocating for any single institution or treatment pathway.
1.1 What a Cancer Second Opinion Actually Involves
A formal cancer second opinion at a comprehensive cancer center is not simply a repeat of the original consultation. It typically involves an independent review of all pathology materials — biopsy slides, tissue blocks, and molecular pathology reports — by specialist pathologists at the receiving institution. This independent pathology review alone carries clinical significance: studies in gastrointestinal, genitourinary, and breast oncology have documented meaningful discordance rates between community and academic center pathology interpretations.
Beyond pathology review, a comprehensive second opinion may include reassessment of staging using the most current criteria, evaluation of molecular biomarker and genomic profiling data to inform targeted therapy eligibility, review of imaging by specialist radiologists, and multidisciplinary tumor board (MDT) discussion involving surgical oncology, medical oncology, radiation oncology, and where relevant, subspecialty surgical disciplines. The outcome may be confirmation of the original plan, refinement of staging or molecular classification, or a substantively different treatment recommendation.
A second opinion at a comprehensive cancer research center involves independent pathology review, molecular profiling assessment, imaging reassessment, and multidisciplinary tumor board evaluation — not simply a repeat consultation. This process changes clinical recommendations in a meaningful proportion of cases and is a recognized component of evidence-based cancer care.
2. UT MD Anderson Cancer Center: Clinical Profile and Second Opinion Access
UT MD Anderson Cancer Center, part of The University of Texas system and located in the Texas Medical Center in Houston, is one of the world's highest-volume dedicated cancer treatment and research institutions. It consistently ranks among the top two cancer hospitals in the United States in annual assessments, reflecting its scope of clinical specialization, research output, and patient volume across virtually all cancer types.
2.1 Clinical Strengths and Specialty Focus
MD Anderson operates disease-focused clinical centers — distinct multidisciplinary programs organized around specific cancer types rather than traditional medical specialty departments. This structure means that a patient with pancreatic adenocarcinoma, for example, is managed by a team whose clinical and research activity is focused exclusively on that disease. Disease-focused programs at MD Anderson include leukemia, lymphoma, myeloma, breast cancer, gastrointestinal cancers, thoracic/lung cancer, genitourinary cancers, head and neck cancers, gynecologic cancers, sarcoma, melanoma, and brain tumors, among others.
MD Anderson is particularly recognized for its leukemia and lymphoma programs, its sarcoma program, its melanoma and skin cancer program, and its large-volume gastrointestinal oncology services. It operates one of the largest clinical trials portfolios of any oncology institution globally, which is a relevant consideration for patients whose cancer type or molecular profile may make them eligible for investigational treatment protocols.
MD Anderson's disease-focused center model means that patients are managed by teams whose entire clinical and research focus is their specific cancer type. For patients with rare or molecularly complex cancers, this disease specificity — combined with access to a large active clinical trials portfolio — may represent a clinically meaningful advantage over generalist oncology programs.
2.2 Second Opinion Access and International Patient Services
MD Anderson offers both in-person and remote second opinion services for international and out-of-state patients. The MD Anderson mySecondOpinion program allows patients to submit medical records, pathology materials, and imaging digitally for review by MD Anderson specialists without requiring travel to Houston. A written expert opinion is typically provided within a defined timeframe, though clinical complexity and case volume can affect turnaround.
For patients who travel to Houston for an in-person consultation, MD Anderson maintains a dedicated International Patient Services department with multilingual staff, translation services, coordination support for international medical record submission, and assistance with practical logistics including accommodation referrals. Language support is available for a large number of languages, which is relevant for patients from non-English-speaking countries accessing the program.
2.3 Cost Considerations for International Patients
MD Anderson operates as a standalone cancer hospital and does not accept all insurance plans, particularly international health insurance policies. International patients without US insurance coverage typically pay out-of-pocket at self-pay rates. A comprehensive in-person second opinion consultation — including specialist physician fees, pathology re-review, and initial consultation — can range from USD $1,500–$5,000+ depending on the extent of evaluation required. Treatment costs if the patient proceeds at MD Anderson are substantially higher and vary considerably by cancer type and treatment protocol.
MD Anderson is a high-volume dedicated cancer institution with disease-focused clinical programs and a large clinical trials portfolio. Remote second opinion services are available via mySecondOpinion. International patients should confirm insurance coverage and cost structure before initiating the process, as self-pay rates at this institution are substantial.
3. Mayo Clinic Oncology: Clinical Profile and Second Opinion Access
Mayo Clinic's oncology second opinion pathway is differentiated by its integrated multidisciplinary evaluation model, in which multiple specialists — medical oncologist, surgical oncologist, radiation oncologist, pathologist, and radiologist — review a case collaboratively within a compressed timeframe, often within one to three days for patients who travel to campus. This "same-day multispecialty" approach reduces the logistical burden of assembling independent specialist opinions across multiple appointments and is a structural feature patients frequently cite as practically advantageous.
Mayo Clinic is a multispecialty academic medical center with primary cancer services based in Rochester, Minnesota, and additional campuses in Phoenix, Arizona, and Jacksonville, Florida. Unlike MD Anderson — which operates exclusively as a cancer institution — Mayo Clinic provides comprehensive medical care across all specialties, with oncology embedded within a broader system that includes cardiology, neurology, gastroenterology, and virtually every other medical discipline.
3.1 Clinical Strengths and Specialty Focus
Mayo Clinic's oncology strength lies in part in the integration of cancer care with its broader clinical expertise. For patients with cancers that have complex systemic implications — hematologic malignancies with cardiac complications, oncology patients requiring complex reconstructive surgery, or patients with multiple simultaneous complex medical conditions — the availability of specialist expertise across disciplines within a single coordinated system may be clinically valuable.
Mayo Clinic is particularly recognized for its hematology and hematologic oncology programs, its gastrointestinal cancer services, its rare cancer expertise, and its thoracic and lung cancer programs. It maintains an active NCI-designated comprehensive cancer center research program and participates in multicenter cooperative oncology group trials. Mayo Clinic also has a robust program in cancer genetics and hereditary cancer risk assessment, which may be relevant for patients seeking evaluation of familial cancer syndromes.
3.2 Second Opinion Pathways at Mayo Clinic
Mayo Clinic offers second opinion consultations through multiple pathways. The Mayo Clinic Online Second Opinion program allows patients to submit medical records electronically for asynchronous review by Mayo specialists and receive a written report, typically within 6–10 business days for most cases. For patients who choose to travel to a Mayo campus, the compressed multispecialty same-week evaluation model is available, which provides a coordinated assessment across relevant disciplines within a few days of arrival rather than requiring multiple return visits.
Mayo Clinic has international patient services at all three campuses, with dedicated international patient coordinators and language interpretation services. It is one of the more widely recognized US academic medical centers for international patient volume, with established relationships with referring physicians and healthcare systems in numerous countries.
3.3 Cost Considerations
Mayo Clinic accepts a range of insurance plans, though coverage for international patients varies. The online second opinion service has a defined fee structure that is published on Mayo Clinic's website and is generally more predictable in cost than an in-person multi-specialist evaluation. International patients seeking in-person evaluation should request a pre-visit cost estimate from Mayo's international patient services office, as costs can vary significantly depending on the scope of evaluation.
Mayo Clinic's oncology second opinion is distinguished by its integrated multispecialty evaluation model and its breadth of systemic medical expertise. Both remote and in-person pathways are available. For patients with cancer and complex co-occurring conditions, Mayo's comprehensive system integration may offer a practical advantage over dedicated cancer-only institutions.
4. Memorial Sloan Kettering Cancer Center: Clinical Profile and Second Opinion Access
Memorial Sloan Kettering Cancer Center, located in New York City with additional regional outpatient facilities across the New York metropolitan area and New Jersey, is a dedicated cancer institution founded in 1884 and widely regarded as one of the foremost cancer research and treatment centers in the world. MSK's combination of clinical volume, translational research output, and specialty depth in surgical oncology makes it a particularly relevant second opinion destination for patients whose primary treatment consideration involves complex cancer surgery.
4.1 Clinical Strengths and Specialty Focus
MSK is distinguished by the depth and volume of its surgical oncology programs. Its surgical oncologists operate in highly subspecialized roles — surgeons at MSK typically focus on a specific organ site or cancer type, accumulating case volumes in their subspecialty that few community or regional cancer centers can match. This subspecialty surgical volume is clinically relevant for cancer types where surgical outcome is strongly correlated with surgeon and institutional experience: pancreatic cancer, esophageal cancer, rectal cancer, complex sarcoma, and certain genitourinary and gynecologic malignancies.
Beyond surgical oncology, MSK has particularly recognized programs in breast cancer, gastrointestinal cancers, thoracic oncology, genitourinary oncology (especially prostate, bladder, and kidney), gynecologic oncology, and hematologic malignancies. MSK's Center for Molecular Oncology provides comprehensive genomic profiling services — including the MSK-IMPACT targeted sequencing panel — that can inform therapeutic decision-making across a broad range of cancer types and is available as a component of second opinion evaluation.
MSK's MSK-IMPACT genomic profiling panel tests for actionable mutations, copy number alterations, and structural variants across hundreds of cancer-relevant genes in a single assay. For patients with cancers where molecular profiling may identify targeted therapy eligibility — including certain lung, colorectal, breast, and rare cancer types — access to this platform as part of a second opinion can directly expand treatment option awareness.
4.2 Second Opinion Access and Remote Services
MSK offers remote second opinion consultations through its MSK Remote Second Opinion program, which allows international and out-of-area patients to submit records electronically for review by MSK specialists. Pathology materials — both physical slides and digital pathology where available — can be submitted for independent review. Written reports are issued following specialist review, with timeframes varying by case complexity and specialist availability.
For patients who choose in-person consultation in New York, MSK has established international patient services including multilingual support and coordination assistance. Its New York City location offers practical advantages for international patients with direct transatlantic or transpacific flight access to major New York airports.
4.3 Cost Considerations
MSK is a private not-for-profit institution and does not accept all insurance plans. International patients without US insurance coverage pay out-of-pocket at self-pay rates that are broadly comparable to MD Anderson. MSK's remote second opinion program has a defined fee structure. Patients considering in-person evaluation or treatment at MSK should request a pre-appointment cost estimate and clarify insurance coverage through the international patient services office before proceeding.
MSK is distinguished by the depth of its subspecialty surgical oncology programs and its genomic profiling capabilities. For patients whose second opinion relates to a cancer where surgical decision-making is central — or where molecular profiling may reveal targeted therapy eligibility — MSK's specific clinical infrastructure may be particularly relevant to evaluate.
5. Side-by-Side Comparison: MD Anderson vs Mayo Clinic vs Memorial Sloan Kettering
The following comparison is intended to support structured evaluation of these three institutions across clinically relevant dimensions. It reflects publicly available institutional information and general clinical positioning — not a ranking, endorsement, or guarantee of outcomes at any institution. Individual patient suitability should be evaluated in consultation with qualified oncology physicians.
| Dimension | UT MD Anderson | Mayo Clinic | Memorial Sloan Kettering |
|---|---|---|---|
| Institution type | Dedicated cancer center (cancer only) | Multispecialty academic medical center | Dedicated cancer center (cancer only) |
| NCI Comprehensive Cancer Center | Yes | Yes | Yes |
| Primary location | Houston, Texas | Rochester, MN (+ AZ, FL) | New York City, NY |
| Clinical organization model | Disease-focused centers | Integrated multispecialty | Subspecialty disease programs |
| Notable specialty strengths | Leukemia, lymphoma, sarcoma, melanoma, GI cancers | Hematologic malignancies, GI cancers, rare cancers, cancer genetics | Surgical oncology, GU cancers, GI cancers, breast, genomic profiling |
| Clinical trials portfolio | Very large | Large | Large |
| Molecular / genomic profiling | Available (Foundation Medicine, in-house panels) | Available (Mayo Clinic molecular profiling) | MSK-IMPACT panel (comprehensive in-house) |
| Remote second opinion program | mySecondOpinion (digital submission) | Mayo Clinic Online Second Opinion | MSK Remote Second Opinion |
| Remote opinion turnaround (typical) | Varies by case complexity | ~6–10 business days | Varies by case complexity |
| In-person evaluation model | Sequential specialist appointments | Compressed same-week multispecialty | Specialist-specific appointment structure |
| International patient services | Dedicated department | Dedicated department (all campuses) | Dedicated department |
| Self-pay second opinion cost (approx.) | USD $1,500–$5,000+ (consultation) | Defined fee (online); variable in-person | USD $1,500–$5,000+ (consultation) |
| Geographic access for international patients | Houston (multiple international flights) | Rochester (regional US hub connections) | New York City (major transatlantic/Pacific hub) |
This comparison reflects institutional characteristics and publicly available information, not a clinical ranking or outcomes guarantee. "Best" institution for any individual patient depends on cancer type, molecular profile, staging, treatment goals, insurance coverage, geographic constraints, and individual clinical circumstances. No single institution is universally superior across all cancer types and patient situations. Patients should evaluate options in consultation with their oncology team.
6. Who Should Consider a Cancer Second Opinion and When
A second opinion is not indicated in every oncology situation with equal urgency. Understanding when a second opinion is most clinically relevant — and when it may be less likely to change the clinical trajectory — helps patients and their families allocate time and resources appropriately. The following framework is intended to support that assessment.
✓ Situations Where Second Opinion May Be Most Valuable
- Rare cancer type with limited community oncology expertise
- Ambiguous or discordant pathology findings
- Recommended treatment involves major irreversible surgery
- Molecular profiling suggests potential targeted therapy eligibility not discussed
- Initial diagnosis of stage III or IV disease before treatment commences
- Recurrence after prior treatment — reassessment of options
- Clinical trial eligibility not evaluated at initial center
- Proposed treatment is experimental or significantly deviates from standard of care
- Patient or family has unresolved uncertainty about the diagnosis
⚠ Situations Requiring Time-Sensitive Judgment
- Rapidly progressing aggressive malignancy where delay in treatment initiation carries clinical risk
- Emergency or semi-urgent surgical oncology situations
- Patient currently receiving active treatment with good response — pausing mid-treatment for second opinion may not be appropriate
- Second opinion already sought at equivalent-level institution with concordant findings
- Logistical or financial barriers to accessing major center second opinion make delay clinically unjustifiable
6.1 The Role of Molecular Profiling in Second Opinion Decisions
One of the most clinically impactful reasons to seek a second opinion at a comprehensive cancer center in the current era of oncology is access to comprehensive molecular and genomic profiling. Comprehensive genomic profiling — testing a tumor biopsy sample for mutations, copy number alterations, and structural variants across hundreds of cancer-relevant genes — can identify targetable alterations that may not have been assessed at the patient's initial institution.
Molecular profiling results can directly affect treatment selection: identifying a targetable EGFR mutation in lung cancer, a BRAF V600E mutation in melanoma or colorectal cancer, HER2 amplification in gastric or breast cancer, or BRCA1/2 alterations in ovarian or prostate cancer, for example, changes the standard treatment pathway. All three institutions compared in this guide have molecular profiling capabilities, though the specific panels and assay platforms differ.
6.2 Timing: When to Initiate a Second Opinion Request
For most patients with newly diagnosed solid tumors who are considering elective treatment, a second opinion process can be initiated concurrently with the diagnostic workup — without necessarily delaying treatment commencement if the second opinion can be completed within an appropriate timeframe. For many common cancer types, a treatment window of four to six weeks for second opinion evaluation is clinically acceptable. However, this judgment must be individualized — some cancer types and presentations require more urgent treatment initiation, and patients should discuss the timing question explicitly with their initial oncology team.
Second opinions at major cancer research centers are most clinically valuable for rare cancers, ambiguous pathology, complex surgical decisions, and cases where molecular profiling may identify targeted therapy eligibility. Timing should be individualized — the urgency of treatment must be balanced against the potential clinical value of expert review, in consultation with the patient's oncology team.
7. International Patient Access: Practical Considerations for Overseas Patients
Yes. All three institutions — UT MD Anderson Cancer Center, Mayo Clinic, and Memorial Sloan Kettering Cancer Center — offer remote second opinion programs that allow international patients to submit medical records, pathology materials, and imaging digitally for specialist review without requiring travel to the United States. Written reports are issued following specialist evaluation. International patients who wish to travel for in-person consultation can do so through each institution's international patient services department, which provides coordination, language assistance, and logistics support.
For patients based in Europe, Canada, Australia, and other countries outside the United States, accessing a second opinion at a major US cancer center involves navigating logistical, financial, and coordination challenges that domestic US patients do not face. Understanding these practical dimensions — and where decision support resources can assist — is important for patients considering this pathway.
7.1 Remote vs In-Person: Which Is More Appropriate for Overseas Patients?
For the majority of international patients seeking a cancer second opinion at one of these institutions, the remote second opinion pathway — submitting records digitally and receiving a written expert report — is the most practically accessible starting point. Remote programs offer the clinical expertise of these institutions' specialists without requiring the time, cost, and health burden of transatlantic or transpacific travel for what may be a consultation rather than treatment.
In-person consultation becomes more relevant when the clinical situation is complex enough that specialist-to-patient interaction is clinically necessary, when the patient is actively considering treatment at the US institution and needs to meet the treating team, or when specific procedures or technologies available at the institution — such as a biopsy, surgical evaluation, or specialized imaging — are required as part of the evaluation.
7.2 Medical Record Preparation and Submission
International patients submitting records for second opinion evaluation at US cancer centers typically need to compile: original pathology reports and, where requested, physical tissue blocks or slides for re-processing and review; radiology imaging in DICOM format on CD, USB drive, or via secure digital transfer; operative reports if prior surgery has been performed; laboratory results including complete blood counts, tumor markers, and relevant chemistry panels; and prior treatment summaries including chemotherapy regimens, doses, and response assessments.
Many international patients face challenges translating medical records from their domestic healthcare system's language and format into English-language documentation that US institutions can efficiently process. This translation and formatting burden is one of the practical reasons patients engaging with international patient coordination services — rather than approaching institutions directly as individuals — report more efficient access to the second opinion process.
7.3 Cost Structure for International Patients Without US Insurance
International patients typically do not have US health insurance coverage and pay self-pay rates. Cost ranges vary by institution, service scope, and whether the consultation is remote or in-person. Approximate published or estimated self-pay ranges for second opinion consultations (remote) are in the range of USD $1,500–$4,500 at these institutions, though actual costs depend on the scope of specialist review required. If treatment is pursued at the US institution, costs are substantially higher and should be estimated in advance through the international patient services office before any commitment is made.
Some international patients evaluate cancer treatment options beyond the United States when cost, waiting times, or specific technology access are considerations. Certain tertiary oncology centers in other countries — including specialized cancer hospitals in major metropolitan centers in Asia — may offer access to advanced treatment technologies, multidisciplinary oncology teams, and international patient coordination services at different cost structures. MedBridge can provide decision support for patients evaluating multiple international oncology pathways, including second opinion access and treatment coordination across geographies.
7.4 Waiting Times and Access Timelines
A practical limitation of major US cancer centers for international patients is appointment availability. New patient appointments at all three institutions can involve waiting periods of several weeks to months for in-person consultation, depending on cancer type, clinical urgency characterization, and specialist availability at the time of request. Remote second opinion programs generally have shorter turnaround times — typically one to four weeks for written report delivery — but are also subject to volume fluctuations.
Patients in clinical situations where treatment delay is a concern should discuss waiting time expectations explicitly with each institution's international patient services office before committing to a specific pathway, and should ensure that their domestic oncology team is aware of and supportive of the second opinion process being pursued in parallel with their ongoing clinical management.
International patients can access second opinions at MD Anderson, Mayo Clinic, and MSK through remote digital submission programs without traveling to the US. Record preparation, translation, and cost coordination are practical barriers that coordination services can assist with. In-person consultation is most relevant for patients actively considering treatment at the US institution or requiring specialist-to-patient evaluation as part of the clinical assessment.
8. How MedBridge Supports International Cancer Second Opinion Decisions
Navigating the process of obtaining a cancer second opinion from a major US institution — while managing an active oncology situation, coordinating medical records across healthcare systems, evaluating cost and logistics, and considering whether additional international treatment options warrant evaluation — is a genuinely complex multi-domain task. MedBridge is designed to provide structured, medically informed decision support for patients undertaking this process from outside the United States.
8.1 How MedBridge Supports the Second Opinion Process
Medical Records Review and Gap Assessment
Submit your existing oncology records — pathology reports, imaging, molecular profiling results, and treatment summaries — through the MedBridge secure platform. Our coordination team reviews your documentation for completeness and identifies gaps or missing components that major US centers typically require before initiating a second opinion review.
Institution Selection Guidance
Based on your cancer type, staging, molecular profile, and clinical situation, MedBridge can provide structured guidance on which institution's specialty profile — MD Anderson, Mayo Clinic, MSK, or other relevant centers — most closely aligns with your specific oncology needs, rather than relying on institutional reputation alone.
Medical Record Translation and Preparation
For patients whose records are in languages other than English, MedBridge facilitates clinically accurate translation of pathology reports, imaging reports, operative summaries, and treatment records — ensuring that the documentation submitted for second opinion review is complete, accurate, and formatted appropriately for the receiving institution.
International Treatment Pathway Evaluation
For patients who wish to evaluate treatment options beyond the US — including consideration of specialized oncology centers in other countries with access to relevant treatment technologies — MedBridge can provide structured information to support a comparative evaluation of multiple international pathways, without advocating for any specific institution or country.
Continuity of Care Coordination
After second opinion reports are received, MedBridge assists patients in communicating findings back to their domestic oncology team — facilitating the translation and interpretation of US specialist reports into formats that support productive conversations with the patient's home country physicians and ensure continuity of care regardless of where treatment ultimately proceeds.
8.2 What MedBridge Will Tell You Honestly
If the clinical situation suggests that the most appropriate pathway is direct treatment at the patient's domestic institution — or that the urgency of the clinical situation does not support the timeline of a remote second opinion at a US center — MedBridge will communicate that clearly and explain the reasoning. Our value is in providing honest, clinically grounded decision support, not in facilitating every pathway request regardless of clinical appropriateness.
Patient Assurance: MedBridge provides medically neutral, patient-interest-first guidance. We do not have commercial referral relationships with MD Anderson, Mayo Clinic, Memorial Sloan Kettering, or any other institution referenced in this article. Our role is to support informed decision-making — not to direct patients toward any specific institution, country, or treatment provider.
Evaluating a Cancer Second Opinion? Get Structured Decision Support.
Submit your case to MedBridge for a clinically grounded assessment of your second opinion options, record preparation requirements, and international oncology pathways — in English, from an independent coordination team.
9. Patient FAQ: Cancer Second Opinions at MD Anderson, Mayo Clinic, and MSK
How do I get a second opinion at MD Anderson, Mayo Clinic, or Memorial Sloan Kettering as an international patient?
All three institutions offer remote second opinion programs that allow international patients to submit medical records, pathology materials, and imaging digitally without traveling to the United States. UT MD Anderson offers the mySecondOpinion program, Mayo Clinic offers its Online Second Opinion service, and Memorial Sloan Kettering offers the MSK Remote Second Opinion program. Each requires submission of pathology reports, imaging, and clinical summaries. International patients should contact each institution's international patient services department to initiate the process and obtain current cost and submission requirements.
Which is better for a cancer second opinion: MD Anderson, Mayo Clinic, or Memorial Sloan Kettering?
No single institution is universally superior for all cancer types and patient situations. UT MD Anderson is particularly recognized for its disease-focused program depth and large clinical trials portfolio across most cancer types. Mayo Clinic's multispecialty integrated model is advantageous for patients with complex co-occurring medical conditions. Memorial Sloan Kettering is especially distinguished by its subspecialty surgical oncology depth and comprehensive genomic profiling capabilities. The most appropriate institution depends on cancer type, staging, molecular profile, and what specific clinical question the second opinion is intended to address.
How much does a cancer second opinion cost at a major US cancer center for an international patient?
International patients without US insurance coverage typically pay self-pay rates. Remote second opinion consultation fees at major US cancer centers generally range from approximately USD $1,500 to $4,500 depending on the scope of specialist review required and the institution's current fee structure. In-person consultation costs are typically higher and vary significantly based on the extent of evaluation. Patients should request a formal cost estimate from each institution's international patient services office before initiating the process, as fees are subject to change and vary by case complexity.
How long does it take to get a cancer second opinion at MD Anderson, Mayo Clinic, or MSK?
Remote second opinion turnaround times vary by institution and case complexity. Mayo Clinic's online second opinion program typically provides written reports within approximately 6–10 business days for most cases. MD Anderson and MSK remote programs have variable timelines depending on specialist availability and case volume. In-person appointment wait times for new patients at all three institutions can range from several weeks to two or more months depending on cancer type and urgency characterization. Patients with time-sensitive clinical situations should communicate urgency explicitly when initiating the request.
Can a cancer second opinion at a major center actually change my diagnosis or treatment plan?
Yes, in a meaningful proportion of cases. Published research across multiple cancer types consistently documents that second opinions at comprehensive cancer centers result in changes to diagnosis, staging, or treatment recommendations in approximately 15–30% of cases. The most common changes involve correction or refinement of pathology interpretation, upstaging or downstaging based on imaging reassessment, identification of molecular alterations that open targeted therapy eligibility, and recommendations for clinical trial participation not previously discussed. The clinical impact of these changes can be substantial for patient outcomes.
Do I need to travel to the United States to get a cancer second opinion from MD Anderson, Mayo Clinic, or MSK?
No. All three institutions offer structured remote second opinion programs that provide specialist review and written report delivery without requiring the patient to travel to the US. Physical pathology materials — tissue blocks or slides — may need to be shipped to the institution for independent pathology review, and DICOM imaging files need to be submitted digitally or on physical media. For most international patients, the remote pathway is the appropriate starting point, with in-person travel considered only if the clinical situation requires direct specialist evaluation or if the patient decides to pursue treatment at the US institution.
What is the difference between a cancer second opinion and seeking treatment at MD Anderson, Mayo Clinic, or MSK?
A second opinion consultation results in a written expert assessment of diagnosis, staging, molecular profiling, and treatment recommendations — it does not initiate treatment at the institution. After receiving a second opinion report, patients may choose to pursue treatment at the same institution, return to their domestic oncology team with the new recommendations, or seek additional opinions elsewhere. Proceeding to treatment at a major US cancer center as an international patient involves a substantially different process, timeline, and cost structure compared to a second opinion consultation, and should be evaluated as a separate decision with full cost and logistics planning.
Is it worth getting a second opinion if I have already started cancer treatment?
A second opinion may still be clinically valuable after treatment has started, particularly if there is uncertainty about treatment response, if a recurrence has occurred, if the treating team is recommending a significant change in protocol, or if new molecular profiling results suggest alternative therapeutic options. Pausing active treatment to seek a second opinion requires careful clinical judgment and should be discussed with the treating oncologist, as some treatment protocols are time-sensitive. Remote second opinion programs can often be initiated without interrupting ongoing treatment, as they require record submission rather than physical travel.
🔑 10. Key Takeaways: Your Complete Decision Support Summary
The most clinically important conclusions from this analysis to support your cancer second opinion evaluation:
All Three Are NCI Comprehensive Centers
MD Anderson, Mayo Clinic, and MSK are all NCI-designated comprehensive cancer centers. The right choice depends on cancer type, clinical complexity, and specific second opinion goals — not institutional reputation alone.
Molecular Profiling Can Change Treatment Options
Comprehensive genomic profiling available at all three centers can identify targetable mutations or clinical trial eligibility that may not have been evaluated at the initial treating institution.
Remote Access Is Available for International Patients
All three institutions offer remote digital second opinion programs. International patients do not need to travel to the US to obtain a written specialist opinion — though physical pathology materials may need to be shipped.
Record Preparation Is a Critical First Step
Complete, translated, and properly formatted medical records are required before any institution can initiate a second opinion review. Incomplete submissions cause delays and may result in requests for additional materials.
Timing Requires Individualized Judgment
Most newly diagnosed solid tumor patients have a clinical window to pursue second opinion evaluation without meaningful harm from delay. Aggressive or rapidly progressing cancers require individualized timing assessment with the treating team.
Second Opinions Change Plans in 15–30% of Cases
Published evidence across cancer types consistently documents meaningful changes to diagnosis, staging, or treatment recommendations at this rate — supporting second opinions as a component of informed cancer care, not a second-guessing exercise.
Medical Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendation. All decisions regarding cancer second opinions, institution selection, and treatment planning should be made in consultation with qualified, licensed oncology physicians familiar with your individual clinical situation. References to UT MD Anderson Cancer Center, Mayo Clinic, and Memorial Sloan Kettering Cancer Center are for informational purposes only. MedBridge has no commercial referral relationship with any of these institutions. MedBridge provides healthcare navigation and medical decision support services; we do not deliver direct clinical care.
© 2025 MedBridge · Cross-Border Healthcare Platform · All Rights Reserved
Most Commented